**KMS Medisurgi Limited** (BSE SME: **540248**) is an Indian healthcare enterprise established in **1999**. The company operates as a specialized manufacturer, job-work provider, and ethical marketer of medical devices and surgical disposables. Positioned as a critical bridge between global technological advancements and the Indian healthcare infrastructure, the company focuses on indigenous manufacturing to reduce import dependence in India—currently the **4th largest market for medical devices in Asia**. --- ### **Core Operational Verticals & Product Ecosystem** KMS Medisurgi operates under a single reportable segment: **"Healthcare Equipments and Supplies."** Its business model is diversified across three functional pillars: * **Advanced Manufacturing & Job Work:** Specializing in the precision **adhesive coating** of diverse substrates, including **non-woven fabrics, PU films, cotton fabrics, and taffeta silk fabrics**. * **Ethical Marketing & Distribution:** Serving as the **Exclusive Distributor** in India for global leaders in surgical disposables and medical equipment. * **Government Supply & Exports:** Operating as a **Government-approved supplier** with a robust distribution network spanning India and international markets. **Comprehensive Product Portfolio:** * **Surgical Disposables:** Including Haemostats and wound care management devices. * **Specialized Equipment:** Urology, General Surgery, Orthopedic, and Physiotherapy equipment. * **Blood Banking:** Specialized devices for blood collection and storage. * **Industrial Components:** Recent expansion into adhesive components for the **Automotive and Electrical** sectors. --- ### **Strategic Growth: Capacity Expansion & Market Diversification** The company is currently executing a transition from a domestic supplier to a diversified global manufacturer through the following initiatives: * **Production Scaling:** The company is installing a **new coating line** designed to **nearly double current production capacity**. This expansion is projected to drive a significant increase in turnover in the upcoming financial cycles. * **R&D and Import Substitution:** A dedicated Research and Development division focuses on identifying and validating raw materials from **indigenous suppliers** to replace expensive imports. * **Process Innovation:** R&D efforts are directed at reducing **mould cycle times**, optimizing **plastic consumption**, and developing new analytical tools to enhance cost-competitiveness. * **Sector Diversification:** To de-risk its revenue streams, the company is leveraging its adhesive expertise to develop components for the **automotive industry**. --- ### **Financial Performance & Capital Structure** KMS Medisurgi has demonstrated consistent top-line growth, although profitability has faced pressure due to expansion costs and competitive dynamics. **Three-Year Financial Summary:** | Metric | FY 2023-24 | FY 2022-23 | FY 2021-22 | | :--- | :--- | :--- | :--- | | **Turnover (Revenue)** | **₹13.88 Crore** | **₹11.03 Crore** | **₹10.32 Crore** | | **Net Profit** | **₹45.38 Lakhs** | **₹57.29 Lakhs** | **₹21.51 Lakhs** | | **Earnings Per Share (EPS)** | **₹1.38** | **₹1.74** | - | | **Dividend Per Share** | **₹0.05 (0.5%)** | **₹0.05 (0.5%)** | - | **Corporate Solvency & Capital Details:** * **Authorized Capital:** **₹3.50 Crore**; **Paid-up Capital:** **₹3.30 Crore** (**33,00,000 shares** at **₹10** par value). * **Working Capital:** Limits maintained within **₹5 Crore**. * **Inventory Model:** Operates a **just-in-time sales model**, resulting in **zero stock of finished goods** at year-end. * **Reserves:** **₹43.98 Lakhs** transferred to reserves for the period ending March 31, 2025. --- ### **Global Footprint & Market Dynamics** The company competes in the global medical adhesives and tapes market, which is ranked among the **top 20 globally**. * **International Reach:** Exports to **USA, Europe, Australia, Russia, UAE (Dubai), Pakistan, Bangladesh, Vietnam, Cambodia, Philippines, and Africa**. * **Demand Drivers:** The clearing of a massive **surgical backlog** in India (estimated at **585,000 cancelled surgeries** during the pandemic) is expected to drive sustained demand for consumables. * **Competitive Landscape:** KMS competes against major global entities including **3M, Coloplast, and Medtronic**, as well as domestic players like **Centaur Pharma and Axiobioslutions**. --- ### **Sustainability & Operational Efficiency** The company has integrated environmental and safety standards into its manufacturing processes: * **Energy Upgrades:** Installation of **Turbo Ventilators**, **LED lighting**, **energy-efficient chillers**, and **high-efficiency motors**. * **Resource Optimization:** Implementation of **higher cavitation moulds** and **energy-saving pumps** to reduce power, fuel, and water consumption. * **Safety Compliance:** Adoption of **Hazard Identification and Risk Assessment (HIRA)** protocols and regular safety mock drills. --- ### **Governance & Leadership** The leadership team was restructured in **2023** to support the current growth phase: * **Mr. Siddharth Kanakia:** Appointed **Managing Director** (5-year term from May 2023). * **Mr. Rohan Kanakia:** Transitioned to **Executive Director**. * **Ms. Monali Kanakia:** Regularized as **Executive Director**. * **Statutory Auditor:** **Naveen Karn & Co.** (Appointed Sept 2023). --- ### **Risk Factors & Audit Observations** Investors should note specific internal control challenges and regulatory disclosures: * **Audit Qualifications:** The **FY 2024-25** financial statements received a **Qualified Opinion**. Key issues include: * **Employee Benefits:** Use of **LIC group gratuity reports** instead of **actuarial valuations**, a departure from **AS-15**. * **Inventory Reconciliation:** Auditors identified **material weaknesses** in internal controls regarding the reconciliation of physical stock records with the books of accounts. * **Inventory Valuation Discrepancies:** * Closing Stock (Sept 30, 2024): **₹275.80 lacs** (Unreconciled). * Closing Stock (March 31, 2025): **₹252.24 lacs** (Unreconciled). * **Related Party Transactions:** Frequent transactions exceeding **10% of annual turnover** require ongoing shareholder approval under **Section 188**. * **Managerial Remuneration:** In **FY 2023-24**, the company sought a waiver for **₹5,88,000** in excess remuneration paid to the MD.